{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-086609","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2024-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.465279+00:00","generated_at":"2026-06-04T02:20:31.119612+00:00","sec_items":["2.05","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Amylyx pulls RELYVRIO from market after Phase 3 miss, cuts 70% of staff","bullets":["Voluntarily discontinues RELYVRIO/ALBRIOZA in U.S. and Canada; no new patients after today.","Workforce reduced ~70%; expects $19M in severance charges; cash runway extended into 2026.","Current patients may transition to free drug program; PHOENIX Open Label Extension ongoing.","Interim data from Phase 2 HELIOS (AMX0035 in Wolfram) due April 2024; webcast Apr 10.","AMX0114 for ALS expects to start clinical trial in 2H 2024; ORION PSP interim analysis mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-086609","json":"https://secwatch.observer/filing/0001193125-24-086609.json","markdown":"https://secwatch.observer/filing/0001193125-24-086609.md","text":"https://secwatch.observer/filing/0001193125-24-086609.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000119312524086609/0001193125-24-086609-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000119312524086609/d780895d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T02:20:31.119612+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7ccf6a8096b711a3d221bb0cfe2bc6aae713bbb0","claim":"Amylyx Pharmaceuticals, Inc. announced a restructuring with charges of approximately $19 million affecting not specified (approximately 70%).","evidence_excerpt":"Plan by the end of the third quarter of 2024. As part of this Restructuring Plan, the Company expects to incur severance and severance-related charges of approximately $19 million. The Company is also evaluating its inventory purchase commitments and the impact its Restructuring Plan will have on inventory obsolescence. The Company may also incur other","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312524086609/0001193125-24-086609-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $19 million"},{"label":"Affected area","value":"not specified"},{"label":"Headcount","value":"approximately 70%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}